| oxaliplatin / Generic mfg. |
| Recruiting | 2 | 104 | RoW | AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan, Leucovorin, 5-fluorouracil | Akeso | Metastatic Colorectal Cancer | 12/24 | 12/26 | | |
| Completed | 2 | 180 | Europe | XELOX, Radiotherapy | Niguarda Hospital | Colo-rectal Cancer | 10/22 | 12/22 | | |
| Active, not recruiting | 2 | 109 | Europe | Bevacizumab, Irinotecan, Folinic acid, Oxaliplatin, 5-FU, Cetuximab | Ludwig-Maximilians - University of Munich | Metastatic Colorectal Cancer | 11/23 | 12/23 | | |
ICONIC, NCT03399071: Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer |
|
|
| Active, not recruiting | 2 | 44 | Europe | FLOT-A | Royal Marsden NHS Foundation Trust, Merck KGaA, Darmstadt, Germany | Gastric Adenocarcinoma, Oesophageal Adenocarcinoma | 11/22 | 08/25 | | |
NCT05350943: HAIC Combined With Toripalimab and Donafenib for Advanced BTC |
|
|
| Enrolling by invitation | 2 | 70 | RoW | HAIC, Gemcitabine, Oxaliplatin, Toripalimab, Donafenib | Lu Wang, MD, PhD | Biliary Tract Adenocarcinoma | 11/22 | 11/23 | | |
NCT04022005: Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL |
|
|
| Completed | 2 | 54 | RoW | Chidamide, Rituximab, Gemcitabine,Oxaliplatin | Sun Yat-sen University | Lymphoma, Large B-Cell, Diffuse | 11/22 | 03/23 | | |
NCT04694183: The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer |
|
|
| Completed | 2 | 37 | RoW | Camrelizumab, SHR-1210, S-1, Tegafur Gimeracil Oteracil Potassium Capsule, Oxaliplatin, Paclitaxel | Quan Wang | Stomach Neoplasms | 05/23 | 05/23 | | |
| Not yet recruiting | 2 | 260 | NA | POF, FOLFOX plus PAC(ip) | Fujian Cancer Hospital | Gastric Cancer | 11/22 | 06/23 | | |
NCT05868317: Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer |
|
|
| Active, not recruiting | 2 | 70 | RoW | Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan), Radiotherapy | Salah Azaïz Cancer Institute | Rectal Cancer, Locally Advanced | 11/22 | 11/23 | | |
BBCAPX-II, NCT04194359: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable | 11/22 | 12/23 | | |
NCT01274962: A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer |
|
|
| Completed | 2 | 180 | Canada | FOLFOX, high dose rate endorectal brachytherapy | Sir Mortimer B. Davis - Jewish General Hospital, Sanofi | Operable T2-3N+M0 Rectal Cancer (Stage III) | 12/22 | 12/22 | | |
NCT04239170: Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 84 | RoW | Camrelizumab(SHR-1210), GEMOX(Gemcitabine, Oxaliplatin) | Peking University | Hodgkin Lymphoma | 12/22 | 12/22 | | |
NCT04249739: Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive |
|
|
| Active, not recruiting | 2 | 93 | RoW | Pembrolizumab, Keytruda, MK3475 | Samsung Medical Center | Gastric Cancer | 02/24 | 03/25 | | |
NCT04663763: Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | PD-1 antibody, Sintilimab, Capecitabine, Oxaliplatin | Zhejiang Cancer Hospital | Locally Advanced Rectal Cancer | 12/22 | 12/25 | | |
NCT04664504: A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk |
|
|
| Recruiting | 2 | 150 | RoW | Concurrent Chemoradiotherapy Radiotherapy, CRT, Short-course Radiotherapy, SCRT, Local dose increase of Short-course Radiotherapy, es-SCRT, Consolidation chemotherapy, XEOLX*4 courses, Adjuvant chemotherapy, XEOLX*6 courses, TME | Jing Jin, M.D. | Rectal Cancer | 12/22 | 12/25 | | |
Re-Play, NCT05354817: Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin |
|
|
| Recruiting | 2 | 25 | RoW | mFOLFIRINOX | Instituto do Cancer do Estado de São Paulo | Colorectal Cancer Stage IV | 12/22 | 12/23 | | |
ALTER-G-001, NCT05262335: Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis |
|
|
| Recruiting | 2 | 116 | RoW | Anlotinib + Oxaliplatin + Capecitabine, Anlotinib + Cisplatin + Paclitaxel/ Docetaxel, Anlotinib + Standard first-line chemotherapy | Ruijin Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastrointestinal Tumors | 12/23 | 12/24 | | |
NCT05361161: Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC) |
|
|
| Not yet recruiting | 2 | 60 | NA | Transarterial Chemoembolization | Gang Wu | Gastric Cancer, Embolization | 12/22 | 12/25 | | |
NCT05545436: Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 34 | RoW | Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine ), Camrelizumab + SOX / XELOX | Third Affiliated Hospital, Sun Yat-Sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Locally Advanced Gastric Cancer | 12/22 | 06/23 | | |
NCT02581215: Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 84 | US | mFOLFIRINOX, Ramucirumab, Cyramza, Placebo | Walid Shaib, MD, Eli Lilly and Company, Hoosier Cancer Research Network | Pancreatic Cancer | 12/22 | 12/23 | | |
NCT04659434: Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL |
|
|
| Not yet recruiting | 2 | 51 | RoW | Sintilimab, IBI308 | Qian Wenbin | Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 12/22 | 12/25 | | |
NCT06417476: Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer |
|
|
| Recruiting | 2 | 66 | RoW | Short-course radiotherapy, Irinotecan, Oxaliplatin, Calcium Formate, Fluorouracil, Long-course chemoradiation, Capecitabine | Pei-Rong Ding, Yunnan Cancer Hospital, Liaoning Tumor Hospital & Institute, Shantou Central Hospital, Fujian Cancer Hospital, Jiangsu Provincial People's Hospital | Rectal Neoplasms | 12/24 | 12/25 | | |
NCT04097028: Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 22 | US | Trifluridine and Tipiracil Hydrochloride, 733030-01-8, Lonsurf, TAS 102, Thymidine, Mixt. with 5-Chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione Monohydrochloride, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Oxaliplatin, 1-OHP, 266046, 61825-94-3, [(1R,-2R)-1,2-cyclohexanediamine-N,N''][oxalato (2--)-O,O'']platinum, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, oxalato (1R,2R-cyclohexanediamine)platinum(II), oxalato (trans-l-1,2-diaminocyclohexane)platinum(II), Oxalatoplatin, OXALIPLATIN,, RP 54780, RP-54780, SR-96669, trans-l DACH oxalatoplatinum | Roswell Park Cancer Institute, National Comprehensive Cancer Network | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | 12/22 | 12/24 | | |
NCT05035381: PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin | Tianjin Medical University Cancer Institute and Hospital | MSI-H Advanced Colorectal Cancer | 12/22 | 12/22 | | |
NCT05004441: Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 43 | RoW | Fruquintinib Combined With mFOLFOX6/FOLFIRI | Zhou Fuxiang, Hubei Cancer Hospital, Henan Cancer Hospital, Xiangya Hospital of Central South University, Huangshi Central Hospital, China | Metastatic Colorectal Cancer | 12/22 | 12/23 | | |
NCT04149015: Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 20 | NA | paclitaxel ,oxaliplatin,fluorouracil | Fujian Cancer Hospital | Gastric Cancer | 12/22 | 12/23 | | |
NCT04224402: Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. |
|
|
| Completed | 2 | 80 | RoW | mFOLFORINOX | Yuhong Li | Pancreatic Cancer Resectable | 12/22 | 12/22 | | |
ChiCTR2000040318: The safety and efficacy of Sindili in the perioperative treatment of locally advanced rectal cancer: single-arm, single-center study |
|
|
| Not yet recruiting | 2 | 35 | | Sintilimab + Radiation therapy + Oxaliplatin + capecitabine | Xuzhou Central Hospital; Xuzhou Central Hospital, self-financing | rectal cancer | | | | |
NCT04523402: Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis |
|
|
| Not yet recruiting | 2 | 100 | NA | Neoadjuvant chemotherapy, Preoperative chemotherapy | Eastern Hepatobiliary Surgery Hospital | Intrahepatic Cholangiocarcinoma Recurrent | 12/22 | 12/23 | | |
ChiCTR2100041919: Initumab combined with chemotherapy or pyrrotinib in the treatment of HER2+ advanced gastric and gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 2 | 50 | | Initomab combined with XELOX ;Initolumab combined with pyrrotinib + paclitaxel | The First Affiliated Hospital of Shandong First Medical University; The First Affiliated Hospital of Shandong First Medical University, China Anti-cancer Association | Gastric cancer | | | | |
NCT04850040: A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin |
|
|
| Not yet recruiting | 2 | 15 | NA | Apatinib Mesylate, Camrelizumab, Oxaliplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Hepatocellular Carcinoma Resectable | 12/22 | 12/24 | | |
ICONA, NCT05054959: Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence |
|
|
| Recruiting | 2 | 62 | Europe | consolidation chemotherapy, induction chemotherapy | Institute of Oncology Ljubljana | Locally Advanced Rectal Cancer | 12/22 | 12/27 | | |
NCT05340231: An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC) |
|
|
| Not yet recruiting | 2 | 100 | NA | TACE protocol, Neoadjuvant Chemotherapy | Gang Wu | Colorectal Cancer | 12/22 | 12/25 | | |
NCT04799548: A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma |
|
|
| Recruiting | 2 | 71 | RoW | Transcatheter Arterial Chemoembolization, Tislelizumab | Shanghai Zhongshan Hospital | Advanced Gastric Cancer | 12/24 | 01/26 | | |
NCT05214339: A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) |
|
|
| Recruiting | 2 | 30 | RoW | Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab | Sun Yat-sen University, Third Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital of Southern Medical University, Xiangya Hospital of Central South University | Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage | 01/23 | 06/23 | | |
NCT06313801: Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions |
|
|
| Recruiting | 2 | 106 | RoW | Docetaxel, Oxaliplatin, Calcium folinate, Fluorouracil, Diagnostic laparoscopy, dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)). | Nizhny Novgorod Regional Clinical Oncology Center | Gastric Cancer | 01/26 | 01/26 | | |
ChiCTR2100051884: Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor secondary prophylaxis in capecitabine combined with oxaliplatin (CapeOX) regimen in the treatment of colorectal cancer |
|
|
| Not yet recruiting | 2 | 20 | | The test drug PEG-rhG-CSF injection was administered 24-48 hours after the end of oxaliplatin intravenous infusion | The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, CSPC Ouyi Pharmaceutical Co., Ltd. | Colorectal cancer | | | | |
| Completed | 2 | 36 | US | Oxaliplatin+Capecitabine+Pembrolizumab | Duke University, Merck Sharp & Dohme LLC | Gastric Cancer, Esophagus Cancer | 02/23 | 02/23 | | |
PIOPPO, NCT03822936: Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | Europe | Preoperative chemotherapy, Folinic acid, Irinotecan, fluorouracil, oxaliplatin, Preoperative radiotherapy, Carbon ion therapy | CNAO National Center of Oncological Hadrontherapy, Foundation IRCCS San Matteo Hospital | Cancer of Pancreas, Pancreas Adenocarcinoma, Resectable Pancreatic Cancer | 02/23 | 02/23 | | |
AFEMA, NCT03279289 / 2016-004076-21: Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen |
|
|
| Completed | 2 | 170 | Europe | Aflibercept, Irinotecan, folinic acid (dl racemic), 5Fluorouracil, 5-FU | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sanofi | Metastatic Colorectal Cancer | 02/23 | 02/23 | | |
NCT04894123: Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients |
|
|
| Terminated | 2 | 1 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, Eloxatin | GERCOR - Multidisciplinary Oncology Cooperative Group, Servier | Colorectal Adenocarcinoma, Oesogastric | 02/23 | 02/23 | | |
PanaMa, NCT01991873 / 2012-005422-30: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 387 | Europe | Maintenance Chemotherapy, Folinic acid + 5-FU (5-Fluorouracil), Panitumumab (Within maintenance phase), Vectibix, mFOLFOX6 (Within re-induction phase), Oxaliplatin + Folinic acid + 5-FU (5-Fluorouracil), Panitumumab (Within re-induction phase) | AIO-Studien-gGmbH, ClinAssess GmbH, Amgen | Metastatic Colorectal Cancer | 02/23 | 02/23 | | |
BTCRC-GI15-015, NCT03283761: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma |
|
|
| Completed | 2 | 39 | US | Nab-paclitaxel 150 mg/m^2, Abraxane®, Oxaliplatin 85 mg/m^2, Eloxatin, 5-FU 1200 mg/m^2 x 2 D, Adrucil, Fluorouracil, Leucovorin 400 mg/m^2 | Al B. Benson, III, MD, Celgene Corporation, Big Ten Cancer Research Consortium | Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer | 12/22 | 01/23 | | |
2018-003112-53: Predictive value of analyzing cancer cells from patients with pancreatic cancer for possible effect of different anti-cancer drugs |
|
|
| Not yet recruiting | 2 | 30 | Europe | Oxaliplatin, Capecitabine, Irinotecan, 5-FU, Gemcitabine, Nab-paclitaxel, Erlotinib, Cisplatin, Docetaxel, Olaparib, Solvent for solution for infusion, Tablet, Concentrate and solvent for concentrate for solution for infusion, Concentrate for dispersion for infusion, Concentrate and solvent for solution for infusion, Powder for solution for infusion, Concentrate for solution for infusion | Vejle Hospital | Pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04264676: Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer |
|
|
| Recruiting | 2 | 294 | RoW | Metronidazole Oral Tablet, Placebo oral tablet | Shanghai Jiao Tong University School of Medicine, Shanghai Municipal Commission of Health and Family Planning, Ruijin Hospital, Fudan University, Shanghai Zhongshan Hospital, Shanghai Shenkang Hospital Development Center | Colorectal Cancer Stage II, Colorectal Cancer Stage III | 03/23 | 03/25 | | |
ChiCTR2100049647: The clinical study of camrelizumab combined with CAPEOX regimen in the first-line treatment of advanced colorectal cancer |
|
|
| Not yet recruiting | 2 | 100 | | Carrelizumab + capecitabine + oxaliplatin | The Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Colorectal cancer | | | | |
NCT05103020: Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases |
|
|
| Recruiting | 2 | 100 | RoW | intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks, IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks | Yonsei University | Metastatic Colorectal Cancer | 03/23 | 03/25 | | |
NCT05237349: Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 38 | RoW | Envafolimab, Immunotherapy, Oxaliplatin, Chemotherapy, S1 | Liangjun Zhu M.M., Zhangjiagang First People's Hospital | Metastatic or Recurrent Gastric Adenocarcinoma | 12/24 | 12/24 | | |
COBP, NCT05585814: Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 12 | NA | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Shanghai Changzheng Hospital | Locally Advanced Colorectal Cancer | 03/23 | 10/25 | | |
NCT05588297: Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases |
|
|
| Not yet recruiting | 2 | 12 | NA | CapOx(Capecitabine+ Oxaliplatin), Bevacizumab, Nivolumab | Shanghai Changzheng Hospital | Colorectal Cancer Liver Metastases | 03/23 | 10/25 | | |
NCT06314334: Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma |
|
|
| Recruiting | 2 | 210 | RoW | Sintilimab+Pegaspargase, P-GemOx, GELAD, IMRT | Fudan University | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | 12/26 | 12/28 | | |
ChiCTR2200057850: Efficacy and safety of xindilimab combined with oxaliplatin / capecitabine (XELOX) in neoadjuvant therapy of locally advanced gastric cancer: a prospective, single center, phase II study |
|
|
| Not yet recruiting | 2 | 46 | | Cindilimab combined with XELOX regimen | Henan Provincial People's Hospital; Henan Provincial People's Hospital, The cost of continuous blood glucose test and ambulatory electrocardiogram in this study shall be paid by themselves according to the hospitalization charging process; However, the cost of subsequent | Gastric cancer | | | | |
MONEO, NCT03979131 / 2019-000782-21: Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) |
|
|
| Active, not recruiting | 2 | 40 | Europe | Avelumab addition to perioperative chemotherapy in GC and GEJC | Vall d'Hebron Institute of Oncology | Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms | 03/23 | 06/26 | | |
NCT05291052: Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors |
|
|
| Recruiting | 2 | 20 | RoW | Tislelizumab, Lenvatinib, Oxaliplatin, Capecitabine | The First Affiliated Hospital with Nanjing Medical University | Biliary Tract Tumor | 03/23 | 03/24 | | |
PRECAM, NCT05216653: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 32 | RoW | Envafolimab, KN053, Oxaliplatin, Capecitabine, Short-course Radiation, TME surgery, total mesorectal excision | Sir Run Run Shaw Hospital | MSS Locally Advanced Rectal Adenocarcinoma | 03/23 | 03/25 | | |
EXPLORE, NCT03038256: Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial |
|
|
| Recruiting | 2 | 244 | RoW | concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME, concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX | Peking University People's Hospital, Peking University Cancer Hospital & Institute, Beijing Friendship Hospital, Peking Union Medical College Hospital, Chinese PLA General Hospital, Shanghai Zhongshan Hospital, Fujian Medical University Union Hospital, Nanfang Hospital of Southern Medical University, Xijing Hospital, Hebei Medical University Fourth Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Affiliated Hospital of Hebei University | Rectal Cancer, Pathological Complete Response, Disease Free Survival | 04/23 | 06/25 | | |
NCT04908813: Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer |
|
|
| Active, not recruiting | 2 | 150 | RoW | HLX22, Placebo, Trastuzumab, Oxaliplatin, Capecitabine | Shanghai Henlius Biotech | Gastric Cancer | 12/24 | 12/25 | | |
| Recruiting | 2 | 102 | RoW | SHR1459 ；YY-20394, Gemcitabine-Oxaliplatin | Jiangsu HengRui Medicine Co., Ltd. | Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | 04/23 | 10/23 | | |
NCT05299476: CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA |
|
|
| Recruiting | 2 | 30 | RoW | CAPOX combined with bevacizumab and Tislelizumab | Chinese PLA General Hospital | Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5 | 12/24 | 06/25 | | |
SLKYLX2023-006, NCT06239870: Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer |
|
|
| Recruiting | 2 | 35 | RoW | Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy | Yunnan Cancer Hospital, Beijing Bethune Charitable Foundation | Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer | 09/25 | 09/25 | | |
2022-001752-42: Durvalumab-based immunotherapy in combination with chemoradiation for patients with early stage esophageal adenocarcinoma |
|
|
| Not yet recruiting | 2 | 32 | Europe | Durvalumab, Oxaliplatin, Calcium Folinate, 5-Fluorouracil, Doxetaxel, Concentrate for solution for infusion, Solution for injection/infusion, Solution for injection, IMFINZI | Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH | T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery, Early stage esophageal cancer, Diseases [C] - Cancer [C04] | | | | |
NCT04221555: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 68 | RoW | Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab | Asan Medical Center | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 04/25 | 04/25 | | |
TAOS-3B, NCT05223088: Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Tislelizumab, Apatinib Mesylate, oxaliplatin, Tegafur | Fujian Cancer Hospital | Immunotherapy, Gastrict Cancer | 04/23 | 04/24 | | |
NCT04834674: DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 20 | RoW | DEB-TACE combined with apatinib and PD-1 antibody | Sichuan Cancer Hospital and Research Institute | Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody | 04/25 | 04/26 | | |
MASTERPLAN, NCT04089150: MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease |
|
|
| Recruiting | 2 | 120 | RoW | Stereotactic Radiotherapy (SBRT), SBRT, Stereotactic Body Radiotherapy, mFOLFIRINOX, modified regimen of oxaliplatin, leucovorin, irinotecan, and fluorouracil (5-FU), Gemcitabine + Nab-paclitaxel, Gemcitabine + Abraxane, Gemcitabine + Capecitabine, GemCap, Pancreatoduodenectomy (Whipple procedure), Whipple | Australasian Gastro-Intestinal Trials Group, Trans Tasman Radiation Oncology Group, Australian Government Department of Health and Ageing | Pancreatic Cancer | 05/23 | 08/23 | | |
NOAHS-ARC, NCT04864067: No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 73 | RoW | Oxaliplatin, All Brands, 5-Fluoracil, Leucovorin, Capecitabine, 5x5 Gy, Quality of Life Questionnaires, DRE/ Endoscopy | Servicio de Salud Metropolitano Sur Oriente | Rectal Cancer | 12/24 | 05/25 | | |
NCT05335460: To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer |
|
|
| Not yet recruiting | 2 | 36 | NA | Envafolimab, XELOX( Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w) | Fujian Cancer Hospital | Colon Cancer | 05/23 | 05/24 | | |
NCT05290116: HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 17 | RoW | HAIC Combined with Tislelizumab and Apatinib | Yunfei Yuan | Intrahepatic Cholangiocarcinoma | 05/23 | 09/23 | | |
NCT06393166: Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 37 | RoW | Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection | Zhejiang Cancer Hospital | Non-Resectable Pancreas Carcinoma | 05/25 | 12/25 | | |
NCT04661150: A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction |
|
|
| Active, not recruiting | 2 | 41 | RoW | Atezolizumab, Tecentriq, Trastuzumab, Herceptin, Capecitabine, Oxaliplatin | Hoffmann-La Roche | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/23 | 08/26 | | |
ELECLA, NCT04188158: Analysis of the Effectiveness of Neoadjuvant Chemotherapy in the Treatment of Colon Cancer Locally Advanced |
|
|
| Recruiting | 2 | 238 | Europe | CAPECITABINE AND OXALIPLATIN | Universidad de León | Locally Advanced Colon Cancer | 05/23 | 03/24 | | |
| Recruiting | 2 | 45 | RoW | HAIC-GEMOX+Cadonilimab+Regorafenib | Fudan University | Intrahepatic Cholangiocarcinoma | 05/25 | 05/26 | | |
NCT05448183: An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 45 | RoW | Toripalimab, Gemcitabine,Oxaliplatin | Xuhua Duan | Extrahepatic Cholangiocarcinoma | 05/23 | 05/24 | | |
| Recruiting | 2 | 53 | RoW | Tislelizumab, Oxaliplatin, S-1, Capecitabine | Sun Yat-sen University | Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach | 11/24 | 11/27 | | |
NCT04217954: HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC |
|
|
| Completed | 2 | 32 | RoW | OXA, 5-FU and bevacizumab plus Toripalimab, FOLFOX | Peking University | Advanced Biliary Tract Cancer | 05/23 | 06/23 | | |
NCT05355155: Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation |
|
|
| Not yet recruiting | 2 | 15 | RoW | Bevacizumab Biosimilar IBI305, FOLFOX4 | The First Affiliated Hospital with Nanjing Medical University | Post-orthotopic Liver Transplantation, Hepatocellular Carcinoma Recurrent | 05/23 | 12/24 | | |
NCT01889303: Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 100 | RoW | DC, Docetaxel Injection， Hengrui Medicine, concurrent chemoradiotherapy with 5-FU/CF, Hengrui Medicine, radiation | Wuhan University | Gastric Cancer | 06/23 | 12/23 | | |
NCT03336216 / 2018-000339-28: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer |
|
|
| Completed | 2 | 206 | Europe, Canada, Japan, US, RoW | Cabiralizumab, BMS-986227, FPA008, Nab-paclitaxel, Abraxane, Onivyde, irinotecan liposome, Nivolumab, Opdivo, BMS-936558, Fluorouracil, 5-Fluorouracil, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan Hydrochloride | Bristol-Myers Squibb | Advanced Pancreatic Cancer | 06/23 | 06/23 | | |
|
GEMOXIA-02, NCT03364530: Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 40 | Europe | Gemcitabine-Oxaliplatin Regimen, Hepatic intra arterial chemotherapy | University Hospital, Montpellier, Federation Francophone de Cancerologie Digestive | Cholangiocarcinoma Non-resectable, Non-metastatic | 06/24 | 06/25 | | |
HCRN GI16-288, NCT03547999: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC |
|
|
| Active, not recruiting | 2 | 78 | US | mFOLFOX6, MVA-BN-CV301, Modified Vaccinia Ankara, CV301, FPV-CV301, Fowl Pox Virus, Nivolumab, Opdivo | Patrick Boland, Bavarian Nordic, Hoosier Cancer Research Network, Bristol-Myers Squibb | Metastatic Colorectal Cancer | 03/24 | 12/24 | | |
|
REVOLUTION, NCT04310176: Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 200 | Europe | Bevacizumab, mFOLFOX6 regimen, mOXXEL regimen, Valproic acid, Capecitabine, 5-fluorouracil | National Cancer Institute, Naples | Ras-mutated Metastatic Colorectal Cancer | 12/23 | 11/24 | | |
NCT04183712: Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA |
|
|
| Recruiting | 2 | 102 | RoW | gemcitabine and oxaliplatin., Gemzar(Eli Lilly and Company) and Aiheng(Jiangsu Hengrui Medicine Co., Ltd.), Afatinib, Gilotrif(Boehringer-Ingelheim) | Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Ruijin Hospital, RenJi Hospital | Gallbladder Carcinoma | 06/23 | 12/23 | | |
NCT04543695: A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 2 | 255 | RoW | Concurrent Chemoradiotherapy, XELOX, CAOPX, mFOLFOX, TME | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Jilin Provincial Tumor Hospital, Cancer Hospital of Guizhou Province, Xijing Hospital | Rectal Cancer | 07/22 | 06/25 | | |
NCT05844371: Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery |
|
|
| Recruiting | 2 | 60 | RoW | tirelizumab, chemotherapy with oxaliplatin + heroda | Yixing People's Hospital | Gastric Cancer | 06/23 | 04/24 | | |
NCT05346874: Neoadjuvant TACiE in Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 37 | RoW | Oxaliplatin, Teysuno, Transarterial chemoembolization (TACE) | Shanghai Zhongshan Hospital | Gastric Cancer | 06/23 | 05/25 | | |
SYSKY-2022-516, NCT06423170: A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs |
|
|
| Recruiting | 2 | 37 | RoW | Camrelizumab plus GEMOX | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unresectable Gallbladder Cancer | 12/25 | 12/26 | | |
NCT03451331: Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer |
|
|
| Completed | 2 | 49 | US | Nivolumab, OPDIVO®, Gemcitabine, Gemzar, Carboplatin, Paraplatin®, Oxaliplatin, Eloxatin | Matthew Galsky, Bristol-Myers Squibb, Hoosier Cancer Research Network | Metastatic Urothelial Cancer | 06/23 | 07/23 | | |
KCSG-HB19-14, NCT04722133: Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy |
|
|
| Completed | 2 | 36 | RoW | HERZUMA+mFOLFOX | Yonsei University | HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer | 06/23 | 06/23 | | |
NCT05348811: HAIC Combined With Donafenib and Sintilimab for Unresectable ICC |
|
|
| Recruiting | 2 | 32 | RoW | HAIC combined with donafenib and sintilimab, HAIC-donafenib-sintilimab | Zhongda Hospital | Cholangiocarcinoma | 06/23 | 07/23 | | |
PERSIST, NCT04982939: Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 210 | RoW | Sintilimab, IBI308, S-1, Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer, Perioperative, Sintilimab | 06/23 | 06/24 | | |
AVETRIC, NCT04513951: AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients |
|
|
| Active, not recruiting | 2 | 58 | Europe | 5Fluorouracil, L-leucovorin, Irinotecan, Oxaliplatin, Cetuximab, Avelumab | Gruppo Oncologico del Nord-Ovest | Metastatic Colorectal Cancer | 06/23 | 07/24 | | |
NCT03435107: Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 33 | RoW | Durvalumab | Asan Medical Center | Metastatic Colorectal Cancer | 06/23 | 12/23 | | |
| Active, not recruiting | 2 | 80 | Europe | Nivolumab, Oxaliplatin, 5-fluorouracil, Leucovorin, FLOX | University Hospital, Akershus, Trondheim University Hospital, Haukeland University Hospital, Hospital of Southern Norway Trust, Oslo University Hospital | Colorectal Cancer Metastatic | 06/24 | 06/25 | | |
CORT, NCT04801511: Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Vitamin C, ascorbic acid | Zhou Fuxiang | Rectal Cancer | 06/23 | 12/24 | | |
NCT05184803: A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer |
|
|
| Recruiting | 2 | 63 | RoW | Docetaxel injection, oxaliplatin, S-1 | Asan Medical Center | Stomach Neoplasm | 06/25 | 12/25 | | |
CIFOXRC, NCT05468177: Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer |
|
|
| Recruiting | 2 | 66 | RoW | neoadjuvant chemotherapy | Tongji Hospital, Huangshi Central Hospital, China, Xiaogan Central Hospital, Ezhou Central Hospital, Jingzhou Central Hospital | Colonic Neoplasms | 06/23 | 06/25 | | |
NCT05620498: Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC. |
|
|
| Recruiting | 2 | 60 | RoW | tislelizumab+lenvatinib+GMOX, tislelizumab+GEMOX | Tianjin Medical University Cancer Institute and Hospital | Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer | 06/23 | 03/24 | | |
NCT04984980: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 37 | RoW | Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab | Fudan University | Biliary Tract Carcinoma, Initially Unresectable | 07/23 | 07/23 | | |
ChiCTR2100048252: A single-center, prospective, randomized controlled clinical study of nab-paclitaxel combined with oxaliplatin and S-1 (S-1) regimen and docetaxel combined with oxaliplatin and S-1 (s-1) regimen for neoadjuvant treatment of locally advanced gastric cancer |
|
|
| Not yet recruiting | 2 | | | Nab-paclitaxel combined with oxaliplatin and S-1 ;Docetaxel in combination with oxaliplatin and S-1 | Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai Shenkang's three-year action plan for ''promoting clinical skills and clinical innovation in municipal hospitals'' | Gastric cancer | | | | |
NCT06036745: Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen |
|
|
| Recruiting | 2 | 20 | RoW | Pembrolizumab + SOX | Shanghai Minimally Invasive Surgery Center | Gastric Cancer Stage IIIB-IIIC | 07/23 | 07/26 | | |